

REMARKS

Applicants are aware that pharmaceutical compositions of IFN- β and of cpn10 are known. However, attention is drawn to the fact that the claim compositions require a combination of these two medicaments.

Accordingly, reconsideration of the restriction requirement and the examination of all claims is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. **524372000100**.

Respectfully submitted,

Dated: April 24, 2003

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125